Akari Therapeutics PLC
NASDAQ:AKTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Akari Therapeutics PLC
Other Liabilities
Akari Therapeutics PLC
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Akari Therapeutics PLC
NASDAQ:AKTX
|
Other Liabilities
$261k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
18%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Liabilities
$17.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Liabilities
$5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
6%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Liabilities
$20.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Liabilities
$7.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Liabilities
$9.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
8%
|
|
Akari Therapeutics PLC
Glance View
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2014-01-31. The firm is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid or leukotriene system and the bioamine system for the treatment of rare and orphan diseases. Its lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4 (LTB4). The company inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement. The company inhibits LTB4 by capturing the fatty acid within the body of the nomacopan protein. The anaphylatoxin (C5a) and the membrane attack complex (MAC) cause and maintain a proinflammatory and prothrombotic state. LTB4 also activates cells via two separate GPCRs and can independently cause and maintain a proinflammatory state.
See Also
What is Akari Therapeutics PLC's Other Liabilities?
Other Liabilities
261k
USD
Based on the financial report for Dec 31, 2025, Akari Therapeutics PLC's Other Liabilities amounts to 261k USD.
What is Akari Therapeutics PLC's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
18%
Over the last year, the Other Liabilities growth was -32%.
